Boston Scientific Corporation $BSX Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 179.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 644,320 shares of the medical equipment provider’s stock after acquiring an additional 413,643 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Boston Scientific were worth $69,206,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of BSX. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after buying an additional 1,697,945 shares during the last quarter. Invesco Ltd. boosted its stake in Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after acquiring an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares in the last quarter. Amundi increased its position in shares of Boston Scientific by 2.6% in the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after purchasing an additional 311,034 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Boston Scientific by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock worth $1,139,938,000 after purchasing an additional 460,580 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.0%

Boston Scientific stock opened at $100.05 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The company has a 50-day simple moving average of $100.09 and a 200-day simple moving average of $102.45. The firm has a market capitalization of $148.26 billion, a P/E ratio of 53.50, a P/E/G ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the previous year, the business posted $0.63 EPS. Boston Scientific’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of several research analyst reports. Wells Fargo & Company increased their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Morgan Stanley lifted their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Truist Financial boosted their price target on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average target price of $123.77.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.